( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Global Drug-coated Balloon Catheter Market" report has been added to ResearchAndMarkets's offering. The global drug-coated balloon catheter market accounted for USD 699 million in 2023 and is estimated to reach USD 1.64 billion by 2034 with a CAGR of 8.
06% during the forecast period 2024-2034. The rising prevalence of cardiovascular diseases, the growing preference for minimally invasive procedures, advances in interventional cardiology, government initiatives, and reimbursement policies, and the growing elderly population will drive market expansion. By type, the paclitaxel segment accounted for the highest revenue-grossing segment in the global drug-coated balloon catheter market in 2023 owing to the proven efficacy in reducing restenosis rates and improving patient outcomes in peripheral artery disease (PAD) treatment.
Additionally, the Sirolimus segment is predicted to grow at the fastest CAGR during the forecast period owing to the superior antiproliferative properties, favorable safety profile, and increasing adoption in coronary artery disease (CAD) interventions. By product, the peripheral vascular disease segment accounted for the highest revenue-grossing segment in the global drug-coated balloon catheter market in 2023 owing to the rising prevalence of peripheral artery disease (PAD) globally and the effectiveness of drug-coated balloon catheters in treating this condition. Additionally.
